PHO

Roper Technologies Inc (NASDAQ:ROP) reported fiscal first-quarter 2024 revenue growth of 14% year-on-year to $1.68 billion, beating the analyst consensus estimate of $1.65 billion. Adjusted EPS of $4.41 beat the analyst consensus estimate of $4.34. Gross profit increased to $1.18 billion from $1.02 billion a year ago. Operating income increased to $483.9 million from $360.1 million the prior quarter. Adjusted EBITDA rose 16% year over year to $676 million, and margin expanded by 60 basis points to 40.2%. Operating cash flow for the quarter totaled $531 million, up by 14% Y/Y. The company held $198.4 million in cash and equivalents as of March 31, 2024. Neil Hunn, Roper Technol

OSLO, Norway, Feb. 22, 2024 /PRNewswire/ --Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that the international multicenter Phase III clinical study of Cevira® (APL-1702), the non-surgical treatment in development for cervical high-grade squamous intraepithelial lesions (HSIL), will be presented for the first time in the form of an oral presentation at the 2024 European Research Organization on Genital Infection and Neoplasia (EUROGIN), held March 13-16 in Stockholm, Sweden: Oral presentation (Abstract No.6802) Photodynamic therapy with APL-1702 for high-grade squamous intraepithelial lesions (HS

OSLO, Norway, Feb. 21, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 114.2 million in the fourth quarter of 2023, an increase of 20% over the prior-year period (Q4 2022: NOK 94.9 million), and EBITDA of NOK 29.9 million (NOK -16.9 million) following solid business development for the Company. Total revenues increased 37% in the fourth quarter of 2023 compared to Q4 2022, including a milestone payment from Asieris related to the license agreement for Cevira®. Photocure has an ambition to deliver 40-70 new and upgraded Saphira™ tower installations in 2024, consolidated product revenue growth of 6% to 9% (constant currency), and positive EBITDA ex

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China. Hexvix, a pharmaceutical product used in the detection of bladder cancer, was licensed to Asieris by Photocure in January 2021, for the registration and commercialization of Hexvix in mainland China and Taiwan.

OSLO, Norway, Nov. 29, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National Medical Products Administration (NMPA) accepted the new drug application (NDA) for Hexvix® (APL-1706) in China. Hexvix, a pharmaceutical product used in the detection of bladder cancer, was licensed to Asieris by Photocure in January 2021, for the registration and commercialization of Hexvix in mainland China and Taiwan. Results of the Hexvix (APL-1706) Phase III clinical trial in China were presented at the 43rd Congress of the Société Internationale d'Urologie (SIU) last month, as a late-brea

OSLO, Norway, Nov. 20, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces its participation in four investor conferences focusing on the healthcare sector in Q4 2023: The SEB Healthcare Seminar will take place in Stockholm, November 21-23, 2023. David Moskowitz, Photocure's Vice President Investor Relations will present a corporate overview on November 22 at 10:40am CET. The 35th Annual Piper Sandler Healthcare Conference will be held in New York City, November 28-30, 2023. Dan Schneider, Photocure's President and CEO will present on November 28 at 9:50am ET. A webcast of the presentation will be available at: Photocure ASA (PHO NO) - 1644046 (webcasts.com)

OSLO, Norway, Oct. 12, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has today unveiled the results of its Hexvix® (APL-1706) Phase III clinical trial in China. A presentation scheduled for today at the 43rd Congress of the Société Internationale d'Urologie (SIU), confirms that, in a Chinese population, Hexvix blue light cystoscopy (BLC®) outperformed white light cystoscopy (WLC) in the detection of bladder cancer, particularly in cases of carcinoma in situ (CIS), and exhibited good tolerability. The highly statistically significant results corroborate the findings of Photocure's own randomized con

OSLO, Norway, Sept. 27, 2023 /PRNewswire/ -- Photocure, The Bladder Cancer Company, announces changes to the composition of its Board of Directors. Reference is made to the stock exchange notice on 9 August 2023 and that Jan H. Egberts, M.D. has decided to step down from his position as Chairperson of the Company's Board of Directors. Dr. Egberts has now resigned from the Board of Directors of Photocure ASA. The current board members of Photocure will constitute the Board of Directors after Dr. Egberts' resignation until the general meeting elects a new Board of Directors. Further, the members of the Board of Directors have, after consultation with the nomination committee, resolved that c

OSLO, Norway, Sept. 20, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that the multinational Cevira® Phase III clinical trial has been completed and successfully met its primary endpoint. Cevira (APL-1702) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL), licensed to Asieris by Photocure. The results of the study will be submitted to the Chinese National Medical Products Administration (NMPA) as part of a new drug application (NDA) in the coming months. This study is a prospec

OSLO, Norway, Aug. 9, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 115.9 million in the second quarter of 2023 (Q2 2022: NOK 99.9 million), and an EBITDA of NOK 23.4 million (NOK 1.4 million). The Company reiterates its 2023 annual guidance of new Saphira™ blue light tower installations in the U.S. expected in the range of 65 to 75, anticipated consolidated product revenue growth above 20%, and positive EBITDA excluding business development spending. "In the second quarter of 2023, Hexvix/Cysview revenue increased 16% year over year driven by higher unit sales in the U.S., price increases and foreign exchange. We generated over NOK 23 million

As July comes to an end, it’s time to take a look at the best- and worst-performing industry ETFs for the month. Among the largest ETFs that represent major U.S. stock indices, the SPDR S&P 500 ETF Trust (NYSE:SPY) returned 3.1% in July, marking its fifth consecutive month of gains. The SPDR Dow Jones Industrial Average ETF (NYSE:DIA) had similar monthly performance, but the Invesco QQQ Trust (NASDAQ:QQQ) outperformed by 3.8%. The strongest performer, though, was the iShares Russell 2000 ETF (NYSE:IWM), which increased by 4.9%. Which industries have performed significantly better than the overall market? Which ones, on the other hand, had a particularly rough month despite the broader

OSLO, Norway, July 6, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that it has completed patient enrollment for the Hexvix® Phase III bridging trial. The objective of the multicenter Phase III trial is to support regulatory approval of Hexvix in Mainland China. The bridging trial is intended to confirm results from prior clinical trials regarding the safety and detection benefits of blue light cystoscopy (BLC®) with Hexvix compared to white light cystoscopy in the diagnosis of non-muscle invasive bladder cancer (NMIBC) in a Chinese population. The clinical trial follows the

OSLO, Norway, May 10, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 105.9 million in the first quarter of 2023 (Q1 2022: NOK 81.4 million) and EBITDA of minus NOK 1.2 million (NOK -13.9 million). Total revenues increased 30% year over year, and 30 high-definition blue light towers were installed in the first quarter (18 new and 12 upgrades). Photocure reiterates its guidance for 2023 and expects to deliver new Saphira™ blue light tower installations in the U.S. in the range of 65 to 75, consolidated product revenue growth above 20%, and positive EBITDA excluding business development spending. "Photocure delivered strong results in the first qua

OSLO, Norway, May 4, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), held its annual general meeting on 3 May 2023 at 17:00 hours (CET). The minutes (corrected) from the general meeting setting out the resolved resolutions are attached hereto. For further information, please contact: Photocure CFO Erik DahlTel: + 47 450 55 000Email: ed@photocure.no About Photocure ASAPhotocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, which makes cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE

OSLO, Norway, May 3, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), held its annual general meeting on 3 May 2023 at 17:00 hours (CET). The minutes from the general meeting setting out the resolved resolutions are attached hereto. For further information, please contact: Photocure CFO Erik DahlTel: + 47 450 55 000Email: ed@photocure.no About Photocure ASAPhotocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, which makes cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For

OSLO, Norway, May 3, 2023 /PRNewswire/ -- Photocure ASA (Photocure) (PHO: OSE) will announce the first quarter 2023 financial results on Wednesday 10 May 2023 at 08:00 CEST and will present a live webcast at 14:00 CEST the same day. The quarterly report and presentation will be published at 08:00 CEST and will be publicly available at www.photocure.com. The investor presentation will be streamed live and be hosted by Dan Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and questions can be submitted throughout the event. The presentation is scheduled to conclude at 14:45 CEST. The streaming event is available through https://channel.royalcast.com/landingpage/hegna

OSLO, Norway, May 2, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that results from the Nordic Registry demonstrating benefits of Blue Light Cystoscopy (BLC®) were presented at the AUA 2023 Conference: the American Urological Association Annual Congress 2023 which was held April 28 - May 1, 2023 in Chicago, IL, USA. The study highlighted that BLC in surveillance of NMIBC* improves the detection of malignant lesions, enhances physicians' confidence, and may reduce patients' tumor burden through immediate fulguration. In addition, Photocure sponsored an educational CME session entitled "How The Experts Treat NMIBC During a BCG Shortage - Integrating Rece

OSLO, Norway, April 12, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), calls for the annual general meeting of Photocure ASA to be held on 3 May 2023 at 17:00 hours (CEST), virtual through the general meeting portal administered by Euronext Securities Oslo (the "Euronext Securities Portal"). The general meeting will be webcasted live and a link will be available on the company's website in due time in advance of the general meeting. It will not be possible to attend in person. Shareholders may also vote in advance or submit a proxy with voting instructions. The notice convening the general meeting, including the agenda and the board's proposals to the matters to be dealt with, is enclosed wi

OSLO, Norway, April 12, 2023 /PRNewswire/ -- Photocure ASA today announces the publication of the Annual Report and integrated ESG report for 2022. The Board of Directors of Photocure ASA has approved the annual accounts for 2022. The financial statements and annual report for the financial year 2022 are together with the ESG report and auditor's report attached to this notice. The ESEF file for 2022 is also attached. The documents are enclosed and also made available at the company's website under https://photocure.com/investors-hub/investors-events-and-presentations. For further information, please contact: PhotocureCFO Erik DahlTel: +47 450 55 000Email: ed@photocure.com About Photocure AS

The Invesco Water Resources ETF (NASDAQ:PHO) is down approximately 21% year-to-date, compared to the S&P 500 which is down roughly 22% year-to-date. Although water utilities have fallen in line with the market, they still make an attractive investment as water is one of the most important resources in the world. The World Health Organization reported 884 million people do not have access to safe drinking water and according to UN-Water more than 2.3 billion people live in water-stressed countries. A global water crisis could continue to worsen with scorching droughts and climate change, which could cause 700 million people to be displaced by intense water scarcity by 2030, the Global Wate

  These are dry times. Droughts are becoming more common and are lasting longer. In the Western United States, for example, the demand for freshwater is outpacing supply, leading states like California to introduce stricter water controls. How dry is the West? A recent study shows the region is suffering the worst drought in over a millennium. According to the 2018 United Nations World Water Development Report, nearly 6 billion peoples will suffer from clean water scarcity by 2050.  For those that don’t believe the science, perhaps the fact that Michael Burry, the investor famous for calling the housing bubble before it burst, has long been focused on investment opportunities in water sca

Transportation Secretary Pete Buttigieg has offered $2.9 billion in grants for state and local bridge, road, and other infrastructure projects, CNBC reports. The grant, part of the bipartisan $1 trillion infrastructure bill approved by President Joe Biden, aimed to fund public works projects. State, regional and local governments will be able to compete for the grant funding through three separate programs. The Transportation Department will award 50% of funding to projects worth over $100 million and share $1 billion in funds over the first year under the National Infrastructure Project Assistance program. The second program called the Infrastructure for Rebuilding America, which cate